Cirrhosis can increase the risk of liver cancer, which also may be fatal.
"In the U.S., mortality due to
cirrhosis is increasing dramatically, with rates expected to triple by the year 2030.
In paediatric patients with
cirrhosis, history of a kidney and/or liver transplant, or genotype 5 or 6 HCV infection, its safety and efficacy are supported by previous studies observed in glecaprevir and pibrentasvir in adults, concluded the agency.
Thus the purpose of study was to determine the sustained virological response in patients with chronic viral hepatitis C genotype 3a irrespective of previous treatment experience or presence of liver
cirrhosis.
The study included 67 (25 (37.3%) female and 42 (62.7%) male) patients with histologically proven
cirrhosis. The mean ages of the patients were 52.3[+ or -]18.6 years for female and 51.2[+ or -]19.5 years for male.
End-stage chronic liver disease (
cirrhosis) is a major cause of morbidity and mortality, and has a large socioeconomic impact because of high health care costs and the patients' inability to work or seek employment.
Keywords: Hepatitis C, Liver
cirrhosis, Osteoporosis.
Increased cardiac output in
cirrhosis was described more than 50 years ago and a hyperdynamic, hyporeactive circulation is today a well-characterised element in the clinical appearance of these patients.
contributed their research paper "Predictive Value of a Noninvasive Serological Hepatic Fibrosis Scoring System in
Cirrhosis Combined with Oesophageal Varices".
High-risk patients usually include those with
cirrhosis caused by hepatitis B or C, or alcoholic or nonalcoholic steatohepatitis.[3] The prevalence of
cirrhosis in patients with HCC is 80-90% worldwide.[4] Usually, the diagnostic tools of HCC include the serum tumor marker a-fetoprotein (AFP),[5] radiographic imaging, and liver biopsy, and liver biopsy is superior to the other tests, with a 96% sensitivity and 95% specificity.[6] However, the diagnosis of HCC sometimes can be difficult.